NCT00736073View on ClinicalTrials.gov

A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis

NACompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

August 31, 2010

Study Completion Date

November 30, 2012

Conditions
Pancreatitis
Interventions
DRUG

aprepitant

one dose of aprepitant (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose

DRUG

Placebo

one dose of placebo (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Duke University

OTHER

NCT00736073 - A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis | Biotech Hunter | Biotech Hunter